Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial of Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies

NCT03663712 is registered in ClinicalTrials.gov with Dan Blazer III, M.D. as lead sponsor.

NCT NCT03663712
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03663712 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial of Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies
Lead sponsor
Dan Blazer III, M.D.
Phase
Phase 1
Overall status
Completed
Start date
May 23, 2019
Completion date
October 13, 2022
Enrollment
28 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

peritoneal surface malignancy